Talzenna

Warnings and Precautions for Talzenna

Talzenna does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.

Myelodysplastic Syndrome and Acute Myeloid Leukemia

Cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported. Complete blood counts should be monitored throughout treatment, and Talzenna should be discontinued if MDS/AML is confirmed.

Myelosuppression

Anemia, neutropenia, and thrombocytopenia are common and may require dose interruption, reduction, or blood count monitoring throughout treatment.

Embryo-Fetal Toxicity

Talzenna may cause fetal harm. Women who could become pregnant should use effective contraception during treatment and for 7 months after the last dose. Men with a female partner who could become pregnant, or is pregnant, should use effective contraception during treatment and for 4 months after the last dose.

How to Access Talzenna in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Talzenna

Talzenna is manufactured and marketed by Pfizer. It is sourced through authorized distribution channels for patients seeking named-patient import into India.

Required Documentation

Patients typically need a valid prescription from a treating oncologist confirming diagnosis and BRCA or HRR gene mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.

Availability

As an FDA-approved PARP inhibitor for BRCA-mutated breast cancer and HRR-mutated prostate cancer, Talzenna is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.

Sourcing and Delivery of Talzenna

NPP sources Talzenna directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.

Storage and Handling

Talzenna should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.

Delivery Timelines

Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.

Availability of Talzenna Across Major Cities in India

Patients across India can access Talzenna through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.

Mumbai

Leading hospitals in Mumbai support oncology care coordination and documentation for Talzenna access.

Delhi

Delhi's major hospitals assist patients with prescription support and documentation for Talzenna.

Bangalore

Bangalore's specialist network offers access coordination for eligible BRCA-mutated cancer patients seeking Talzenna.

Chennai

Chennai-based oncology specialists coordinate Talzenna access alongside comprehensive cancer care.

Hyderabad

Hyderabad's care institutions support patients pursuing Talzenna therapy.

Kolkata

Kolkata's specialist centers help coordinate documentation and treatment access for Talzenna.

Pune

Pune-based specialists assist with prescription support and Talzenna treatment planning.

Ahmedabad

Ahmedabad's specialty hospitals support the import and treatment process for Talzenna.

Kochi

Kochi's specialist units assist patients with the documentation needed for Talzenna access.

Chandigarh

Chandigarh's care centers support Talzenna treatment coordination for patients from North India.

Jaipur

Jaipur's specialists help patients navigate the Talzenna access process.

Lucknow

Lucknow-based centers assist patients pursuing Talzenna therapy.

Bhubaneswar

Bhubaneswar's institutions support access to Talzenna for eligible patients.

Guwahati

Guwahati's specialists help coordinate Talzenna access for patients across the Northeast.

Patients in other cities across India can also access Talzenna through NPP's nationwide coordination network.